Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

Trial Profile

A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Mitoxantrone (Primary)
  • Indications Acute myeloid leukaemia; Neoplasms by histologic type
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2021 Results assessing safety and efficacy of combining gemtuzumab ozogamicin with dose-escalated mitoxantrone as initial therapy for fit adults with newly diagnosed acute myeloid leukemia or high-grade myeloid neoplasm, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 12 Jan 2021 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top